Ethical Framework for Medication Discontinuation in Nursing Home Residents with Limited Life Expectancy

Clinics in Geriatric Medicine

Volumn 28, Issue 2, 2012, Pages 255-272

  Tjia, Jennifer ^a   Givens, Jane ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Hebrew SeniorLife Institute for Aging Research   (United States)

Author keywords

Dementia; Discontinuation; End of life; Ethics; Medication; Nursing home

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; ANTIBIOTIC AGENT; ANTIPARKINSON AGENT; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BUTALBITAL; CAFFEINE; CARISOPRODOL; CILOSTAZOL; CYANOCOBALAMIN; DONEPEZIL; FERROUS SULFATE; FOLIC ACID; FUROSEMIDE; GLIBENCLAMIDE; LISINOPRIL; MECLOZINE; METFORMIN; MULTIVITAMIN; NEUROLEPTIC AGENT; OMEPRAZOLE; PARACETAMOL; POTASSIUM; SIMVASTATIN; SPIRONOLACTONE; UNINDEXED DRUG; ZINC;

ADVERSE DRUG REACTION; AGED; AGITATION; ANEMIA; ANXIETY; ASPIRATION PNEUMONIA; BENEFICENCE; CASE REPORT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG MONITORING; DRUG WITHDRAWAL; DYSKINESIA; ECONOMIC ASPECT; FEMALE; HEADACHE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INSOMNIA; JUSTICE; KIDNEY FAILURE; LEGAL ASPECT; LIFE EXPECTANCY; LOW BACK PAIN; LUNG EMBOLISM; MEDICAL DECISION MAKING; MEDICAL ETHICS; MULTIINFARCT DEMENTIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING HOME PATIENT; OSTEOPOROSIS; PATIENT AUTONOMY; PATIENT PREFERENCE; PERIPHERAL VASCULAR DISEASE; PHARMACIST; POLYPHARMACY; PRESCRIPTION; PROGNOSIS; PSYCHOSIS; QUALITY OF LIFE; RESOURCE ALLOCATION; RESTLESSNESS; REVIEW; RIGIDITY; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOCIAL ASPECT; TREMOR; URINARY TRACT INFECTION; VERTIGO;

AGED; AGED, 80 AND OVER; DECISION MAKING; DRUG UTILIZATION REVIEW; ETHICS, MEDICAL; FEMALE; HOMES FOR THE AGED; HUMANS; LIFE EXPECTANCY; MALE; MORAL OBLIGATIONS; NURSING HOMES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT PREFERENCE; POLYPHARMACY; PRINCIPLE-BASED ETHICS; VALUE OF LIFE;

EID: 84859704789     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2012.01.010     Document Type: Review

References (36)

1. Gurwitz J.H., Field T.S., Judge J., et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005, 118(3):251-258.
2. Doshi J.A., Shaffer T., Briesacher B.A. National estimates of medication use in nursing homes: findings from the 1997 Medicare Current Beneficiary Survey and the 1996 Medical Expenditure Survey. J Am Geriatr Soc 2005, 53(3):438-443.
3. Beers M.H., Ouslander J.G., Rollingher I., et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Int Med 1991, 151(9):1825-1832.
4. Beers M.H., Ouslander J.G., Fingold S.F., et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med 1992, 117(8):684-689.
5. Perri M., Menon A.M., Deshpande A.D., et al. Adverse outcomes associated with inappropriate drug use in nursing homes. Ann Pharmacother 2005, 39(3):405-411.
6. Avorn J., Gurwitz J.H. Drug use in the nursing home. Ann Intern Med 1995, 123(3):195-204.
7. Field T.S., Gurwitz J.H., Avorn J., et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001, 161(13):1629-1634.
8. Lau D.T., Kasper J.D., Potter D.E.B., et al. Hospitalization and Death Associated With Potentially Inappropriate Medication Prescriptions Among Elderly Nursing Home Residents. Arch Intern Med 2005, 165(1):68-74.
9. Tjia J., Rothman M.R., Kiely D.K., et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc 2010, 58(5):880-888.
10. Riechelmann R.P., Krzyzanowska M.K., Zimmermann C. Futile medication use in terminally ill cancer patients. Support Care Cancer 2009, 17(6):745-748.
11. Omnibus Budget Reconciliation Act of 1987 [OBRA-87]. Public Law No. 100-203. Subtitle C: Nursing Home Reform. F329 Unnecessary drugs. US Congress. Washington DC, 1987.
12. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997, 157(14):1531-1536.
13. Transmittal 22. (December 15 2006.) Centers for Medicare and Medicaid Services, Accessed October 17, 2011. http://www.cms.hhs.gov/transmittals/downloads/R22SOMA.pdf.
14. Stevenson J.P., Currow D.C., Abernethy A.P. Frameworks for prescribing in comorbid illness. J Pain Symptom Manage 2007, 34(2):117-118.
15. Holmes H.M., Hayley D.C., Alexander G.C., et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006, 166(6):605-609.
16. Rochon P.A., Gurwitz J.H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997, 315(7115):1096-1099.
17. Jonsen A., Siegler M., Winslade W. Clinical Ethics 2006, McGraw-Hill, New York. 6th ed.
18. Chartbook: Medicaid Pharmacy Benefit Use and Reimbursement in 2004 Mathematica Policy Research, Accessed October 25, 2011. https://www.cms.gov/MedicaidDataSourcesGenInfo/downloads/Pharmacy_Rx_Chartbook_2004.pdf.
19. Field M., Cassell C. Institute of Medicine Report. Approaching death: improving care at the end of life 1997, National Academy Press, Washington DC.
20. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
21. Woodward M. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res 2003, 33:323-328.
22. Parsons C., Hughes C.M., Passmore A.P., et al. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying?. Drugs Aging 2010, 27(6):435-449.
23. Parsons C., Briesacher B.A., Givens J.L., et al. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc 2011, 59(7):1253-1259.
24. Fillit H., Hofbauer R.K., Setyawan J., et al. Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease. J Am Med Dir Assoc 2010, 11:636-644.
25. Daiello L.A., Ott B.R., Lapane K.L., et al. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 2009, 7:74-83.
26. Rainer M., Mucke H.A.M., Krüger-Rainer C., et al. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. J Neural Transm 2001, 108:1327-1333.
27. Lee J., Monette J., Sourial N., et al. The use of a cholinesterase inhibitor review committee in long-term care. J Am Med Dir Assoc 2007, 8:243-247.
28. Huang H.-Y., Caballero B., Chang S., et al. The Efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a national institutes of health state-of-the-science conference. Ann Int Med 2006, 145(5):372-385.
29. Brauner D.J., Muir J.C., Sachs G.A. Treating nondementia illnesses in patients with dementia. JAMA 2000, 283(24):3230-3235.
30. Butler R.N. Ageism in America. The Anti-Ageism Taskforce at the International Longevity Center Accessed October 26, 2011. http://www.graypanthersmetrodetroit.org/Ageism_In_America_-_ILC_Book_2006.pdf.
31. Bain K.T., Holmes H.M., Beers M.H., et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc 2008, 56(10):1946-1952.
32. Jachuck S.J., Brierley H., Jachuck S., et al. The effect of hypotensive drugs on the quality of life. J R Coll Gen Pract 1982, 32(235):103-105.
33. Ray W.A., Taylor J.A., Meador K.G., et al. Reducing antipsychotic drug use in nursing homes. A controlled trial of provider education. Arch Intern Med 1993, 153(6):713-721.
34. Bridges-Parlet S., Knopman D., Steffes S. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. J Geriatr Psychiatry Neurol 1997, 10(3):119-126.
35. Findlay D.J., Sharma J., McEwen J., et al. Double-blind controlled withdrawal of thioridazine treatment in elderly female inpatients with senile dementia. Int J Ger Psych 1989, 4(2):115-120.
36. Fuchs V.R. The doctor's dilemma-what is "appropriate" care?. N Engl J Med 2011, 365(7):585-587.